Please login to the form below

Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

FDA adcomm split on Sanofi’s type 1 diabetes drug

Current SGLT2-selective drugs – such as Johnson &Johnson’s Invokana, Eli Lilly/Boehringer Ingelheim's Jardiance and Farxiga from AstraZeneca – are approved only for type 2 diabetes.

Latest news

AZ says target of $45bn sales by 2023 still achievable

AZ’s CEO also highlighted diabetes therapy Farxiga (dapagliflozin), which grew by a third to $994m in the nine-month period despite a tough competitive environment. ... The study showed Farxiga cut hospitalisations for heart failure and cardiovascular
New cancer drugs can’t quite plug the revenue hole at AZ

Other bright spots for AZ included the continued growth if antiplatelet drug Brilinta (ticagrelor), up 18% to $609m, diabetes drug Farxiga (dapagliflozin) which leaped 36% to $639m, and new asthma drug
J&J’s Invokana aces diabetic kidney disease trial, setting up filings

risk of lower-limb amputation in diabetics, putting it at a disadvantage compared to rival SGLT2 drugs such as Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) and AstraZeneca’s Farxiga
J&J says real-world data finds no amputation risk for Invokana

Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) has also continued to gather pace with the company reporting sales rose 29% to just over $1bn last year.
The year of the blockbuster

entrant to an increasingly crowded market and will compete directly with first-to-market Invokana, as well as Farxiga and Jardiance.

More from news
Approximately 4 fully matching, plus 23 partially matching documents found.

Latest Intelligence

China: AstraZeneca’s new engine for growth and innovation

One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
Transforming times at AstraZeneca

and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Director: Competitive Salary Offered

Account Director – Healthcare Marketing – Berks: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Associate Director: £75, 000-90, 000

Account Director – Health Policy – Global Agency: Salary TBC

Senior Medical Writer: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Account Manager: Competitive Salary Offered

Business Director: Competitive Salary Offered

Medical Writer: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Manager / Account Director: Competative

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Global Business Development Director – Health Education: excellent commission

Account Director, Medical Education: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...